Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may unlock why antipsychotics work for some, not others

NCT ID NCT03442101

Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 156 people experiencing their first episode of psychosis who have never taken antipsychotic medication. Participants receive standard treatment with risperidone or aripiprazole and undergo brain scans four times over 32 weeks. The goal is to identify brain differences that predict who will respond well to treatment, which could lead to more personalized care and new therapies for those who don't improve.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
risperidone and aripiprazole (antipsychotic medications)
What this could lead to
If successful, this could help doctors predict which patients will respond to standard antipsychotics and point toward new treatments for those who don't.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve care. The findings may not apply to all patients with psychosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

156 people

The number who actually took part.

Started

Apr 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

First episode psychosis subjects

Ages

17 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A diagnosis of first episode psychosis * Never been treated with an antipsychotic medication * Between the age of 17 and 35 Exclusion Criteria: * Inability to sign informed consent assessed by the Evaluation to sign - - Consent form * Poorly controlled acute or chronic medical and neurological conditions * History of head trauma with loss of consciousness for \>2 minutes * Clinically significant depression, hypomania, or mania * Active substance abuse or dependence (except for nicotine) * Suspected substance-induced psychosis * Treatment with drugs known to affect brain glutamate levels * Pregnant females

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychosis

Contacts and locations

Locations

  • Sparks Center

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.